Tumor growth effects of rapamycin on human biliary tract cancer cells

Table 2 Percentages of TFK-1 in each phase of the cell cycle after 48 hours of exposure to different dosages of rapamycin

Group	Apoptosis^a			G0/G1 phase			G2 + M phase			S phase
	Mean	±SE	P ^b	Mean	±SE	P ^b	Mean	±SE	P ^b	Mean	±SE	P ^b
control	0.15	0.03		37.78	1.67		39.00	1.33		8.9	0.34
rapa 1 ng/mL	0.11	0.02	0.21	51.75	1.07	<0.001	33.72	0.92	<0.05	5.55	0.43	<0.001
rapa 5 ng/mL	0.09	0.01	<0.05	50.74	1.31	<0.001	35.45	0.69	<0.05	4.10	0.16	<0.001
rapa 10 ng/L	0.08	0.01	<0.05	49.53	1.15	<0.001	35.28	0.66	<0.05	4.38	0.30	<0.001
rapa 20 ng/mL	0.15	0.01	0.92	47.26	1.10	<0.001	35.97	0.87	0.09	5.61	0.13	<0.001
rapa 50 ng/mL	0.19	0.02	0.25	49.86	2.17	<0.001	37.67	1.11	0.46	3.21	0.33	<0.001

Cell cycle analysis of EGI-1 and TFK-1 cell lines 48 hours after treatment with rapamycin at doses of 1, 5, 10 and 20 ng/mL, with 5-bromo-2′-deoxyuridine and 7-aminoactinomycin D staining. ^aSub G1-region, indicating cells with small DNA fragments, a typical feature of apoptosis; ^bt-test was performed; while a Levene test was performed in case of unequal variances, P <0.05 was considered significant. rapa: rapamycin; SE: standard error of the mean.

ISSN: 2047-783X